Risperidone in Psychotic Combat-Related Posttraumatic Stress Disorder: An Open Trial
The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
RATIONALE: Psychotic symptoms that frequently occur in combat-related posttraumatic stress disorder (PTSD) complicate its pharmacotherapy. We hypothesized that war veterans with psychotic PTSD, resistant to prior antidepressant treatment, would respond well to 6 weeks of treatment with the atypical antipsychotic risperidone, given as a monotherapy. METHOD: Twenty-six male war veterans with psychotic PTSD (DSM-IV) completed the 6-week inpatient treatment with risperidone (2-4 mg/day) during the period from November 1999 through December 2002. The primary outcome measure was change from baseline to endpoint (6 weeks) in Positive and Negative Syndrome Scale (PANSS) total and subscale scores. Secondary outcome measures were changes in PTSD Interview (PTSD-I) and Clinical Global Impressions-Severity of Illness scale (CGI-S) total and subscale scores. Clinical improvement was assessed by CGI-S, CGI-Improvement scale, and Patient Global Impression of Improvement scale, while adverse events were recorded by Drug-Induced Extrapyramidal Symptoms Scale. RESULTS: Treatment with risperidone for either 3 or 6 weeks in an open trial significantly reduced total and subscales scores on the PANSS and on the PTSD-I and CGI-S when compared to baseline scores in patients with psychotic PTSD. CONCLUSION: Our preliminary data from the open trial indicate that risperidone decreased most of the psychotic and PTSD symptoms. Psychotic PTSD patients, unresponsive to antidepressant treatment, improved significantly after treatment for either 3 or 6 weeks with risperidone.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sautter, F. J., Bissette, G., Wiley, J., Manguno-Mire, G., Schoenbachler, B., Myers, L., Johnson, J. E., Cerbone, A., & Malaspina, D. (2003) · Biological Psychiatry · doi:10.1016/s0006-3223(03)00571-7 · Cited by 162
Cited by
Pharmacologic alternatives to antidepressants in posttraumatic stress disorder: A systematic review
Berger, W., Mendlowicz, M. V., Marques-Portella, C., Kinrys, G., Fontenelle, L. F., Marmar, C. R., & Figueira, I. (2009) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2008.12.004 · Cited by 347
Braakman, M. H., Kortmann, F. A. M., & Van Den Brink, W. (2009) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2008.01252.x · Cited by 128
“(30) n = 26 (all PTSD-SP) All male Croatian war veterans In-patients SCID; CAPS; PTSD-I; HAM-D; PANSS Risperidone reduced psychotic and PTSD symptoms in PTSD-SP”
BackgroundCarey, P., Suliman, S., Ganesan, K., Seedat, S., & Stein, D. J. (2012) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.2238 · Cited by 70
“Our data are encouraging in that proportionately fewer patients (29%) were non-responders to olanzapine (Stein et al., 2002; Hamner et al., 2003; Pivac et al., 2004; Bartzokis et al., 2005; Kozaric-Kovacic et al., 2005; Pivac and Kozaric-Kovacic, 2006; KozaricKovacic and Pivac, 2007).”
BackgroundResultInfluentialPharmacologic Treatment of Posttraumatic Stress Disorder Among Privately Insured Americans
Harpaz-Rotem, I., Rosenheck, R. A., Mohamed, S., & Desai, R. A. (2008) · Psychiatric Services · doi:10.1176/ps.2008.59.10.1184 · Cited by 51
Metadata
- Authors
- Kozarić-Kovacić, D., Pivac, N., Mück-Seler, D., & Rothbaum, B. O.
- Venue
- The Journal of Clinical Psychiatry
- Publisher
- Physicians Postgraduate Press, Inc
- Published
- 2005-07-15
- Volume
- 66
- Issue
- 07
- Pages
- 922-927
- ISSN
- 0160-6689 (ISSN-L)
- OpenAlex
- W2089051089
- Cited by
- 52
- References
- 1
- FWCI
- 6.61
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Risperidone in Psychotic Combat-Related Posttraumatic Stress Disorder: An Open Trial. https://app.cochat.ai/papers/10.4088/jcp.v66n0716
- The paper
- Kozarić-Kovacić, D., Pivac, N., Mück-Seler, D., & Rothbaum, B. O. (2005). Risperidone in Psychotic Combat-Related Posttraumatic Stress Disorder: An Open Trial. The Journal of Clinical Psychiatry. https://doi.org/10.4088/jcp.v66n0716
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.